Summary by Moomoo AI
On March 1, 2024, Shattuck Labs, Inc., a clinical-stage biotechnology company, announced the expansion of its Board of Directors with the appointment of Dr. Clay Siegall and Dr. Kate Sasser, effective immediately. Dr. Siegall, with a notable background as President, CEO, and Chairman of Immunome, Inc., brings extensive experience in drug development and pharmaceutical leadership. Dr. Sasser, currently the Chief Scientific Officer at Tempus AI, has a strong track record in translational research and precision medicine. Both appointees are expected to receive compensation in line with the company's non-employee director policy and will enter into the company's standard indemnification agreement. The appointments come at a strategic time as Shattuck Labs prepares for significant clinical updates and potential expansion of pivotal studies for its lead program SL-172154, which is currently in multiple Phase 1 trials. The company, which specializes in developing bifunctional fusion proteins for cancer and autoimmune disease treatment, anticipates these appointments will contribute to its transition to late-stage clinical development and support its growth objectives.